Here, except for MDS-derived AML, an analysis of 714 patients found that the frequency of EZH2 mutations was only 1.8% in de novo AML (Wang et al., 2013), and this reflected uncertainties in the prevalence and prognostic value of EZH2 mutations in AML individuals. This evidence concerns the gene EZH2 and myelodysplastic syndrome.